Gastroenterology

Gastroenterology

Volume 112, Issue 2, February 1997, Pages 463-472
Gastroenterology

Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients

https://doi.org/10.1053/gast.1997.v112.pm9024300Get rights and content

Abstract

BACKGROUND & AIMS: Few data are available concerning the long-term prognosis of chronic liver disease associated with hepatitis C virus infection. This study examined the morbidity and survival of patients with compensated cirrhosis type C.

METHODS: A cohort of 384 European cirrhotic patients was enrolled at seven tertiary referral hospitals and followed up for a mean period of 5 years. Inclusion criteria were biopsy-proven cirrhosis, abnormal serum aminotransferase levels, absence of complications of cirrhosis, and exclusion of hepatitis A and B viruses and of metabolic, toxic, or autoimmune liver diseases.

RESULTS: Antibodies against hepatitis C virus were positive in 98% of 361 patients tested. The 5-year risk of hepatocellular carcinoma was 7% and that of decompensation was 18%. Death occurred in 51 patients (13%), with 70% dying of liver disease. Survival probability was 91% and 79% at 5 and 10 years, respectively. Two hundred five patients (53%) were treated with interferon alfa. After adjustment for clinical and serological differences at baseline between patients treated or not treated with interferon, the 5-year estimated survival probability was 96% and 95% for treated and untreated patients, respectively.

CONCLUSIONS: In this cohort of patients, life expectancy is relatively long, in agreement with the morbidity data showing a slowly progressive disease.

(Gastroenterology 1997 Feb;112(2):463-72)

References (0)

Cited by (1278)

  • Hepatitis C

    2023, The Lancet
  • Hepatitis C: epidemiology, natural history, and diagnosis

    2023, Comprehensive Guide to Hepatitis Advances
View all citing articles on Scopus
View full text